These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7762066)

  • 21. High resolution HLA class I and II typing and CTLp frequency in unrelated donor transplantation: a single-institution retrospective study of 69 BMTs.
    El Kassar N; Legouvello S; Joseph CM; Salesses P; Rieux C; Cordonnier C; Vernant JP; Farcet JP; Bierling P; Kuentz M
    Bone Marrow Transplant; 2001 Jan; 27(1):35-43. PubMed ID: 11244436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency analysis of cytotoxic T lymphocyte precursors in search for donors in bone marrow transplantation.
    Cukrová V; Dolezalová L; Loudová M; Matĕjková E; Korínková P; Lukásová M; Starý J
    Neoplasma; 1995; 42(1):3-8. PubMed ID: 7617071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
    Mackinnon S; Hows JM; Goldman JM; Arthur CK; Hughes T; Apperley JF; Jones L; Batchelor JR; Brookes P; Catovsky D
    Exp Hematol; 1990 Jun; 18(5):421-5. PubMed ID: 2338131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation.
    Kaminski E; Hows J; Man S; Brookes P; Mackinnon S; Hughes T; Avakian O; Goldman JM; Batchelor JR
    Transplantation; 1989 Oct; 48(4):608-13. PubMed ID: 2508280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
    Gajewski J; Gjertson D; Cecka M; Tonai R; Przepiorka D; Hunt L; Giralt S; Chan KW; Feig S; Territo M; Andersson B; van Besien K; Khouri I; Fischer H; Babbitt L; Ippolitti C; Schiller G; Lill M; Warkentin D; Neumann J; Petz L; Terasaki P; Champlin R
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):76-82. PubMed ID: 9267667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
    Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
    Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bone marrow transplantation from unrelated donors in chronic myeloid leukemia: the results in 15 patients].
    Sierra J; Carreras E; Rovira M; Batlle M; Urbano-Ispizua A; Marín P; Besson I; Merino A; Algara M; Cervantes F
    Med Clin (Barc); 1995 May; 104(18):689-94. PubMed ID: 7769878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
    Huang H; Lin M; Meng H
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre.
    Vossen JM; Donker AE; Heemskerk MB; Lie JL; van Weel-Sipman MH; Bredius RG; Bakker JD; Egeler RM; Oudshoorn M
    Bone Marrow Transplant; 2010 Jan; 45(1):87-95. PubMed ID: 19448680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow transplantation for chronic myelogenous leukemia in blastic phase using a phenotypically identical unrelated volunteer donor. Nagoya Bone Marrow Transplantation Group (NBMTG), Tokai Marrow Donor Bank (TMDB).
    Akatsuka Y; Kodera Y; Yamamoto K; Minami S; Miyamura K; Morishita Y; Morishima Y; Saitoh H; Horibe K; Yamauchi T
    Int J Hematol; 1992 Jun; 55(3):249-53. PubMed ID: 1498315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors.
    Goldman JM; Mackinnon S
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():38-9. PubMed ID: 2627622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.